Clinical toxicity of interleukin-2. (Q33355316)

26 July 2017

1 reference

title

Clinical toxicity of interleukin-2. (English)

1 reference

26 July 2017

T Vial

1

0 references

author name string

J Descotes

series ordinal

2

1 reference

26 July 2017

publication date

1 November 1992

1 reference

26 July 2017

1 reference

26 July 2017

volume

7

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

417-433

1 reference

Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin

26 July 2017

cites work

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Thyroid disorders in 2 cases of acute myeloid leukaemia following treatment with recombinant interleukin-2 infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Human recombinant interleukin-2 as an experimental therapeutic

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Pulmonary edema as a complication of interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Association of interleukin-2 therapy with staphylococcal bacteremia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Clinical Use of Biologic Response Modifiers in Cancer Treatment: An Overview Part II. Colony-Stimulating Factors and Interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Increased incidence of hypersensitivity to iodine-containing radiographic contrast media after interleukin-2 administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

The effect of intravenous interleukin-2 on brain water content

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

The appearance of hypodense eosinophils during interleukin-2 treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Fibromyalgia and interleukin-2 therapy for malignancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Myocardial injury after interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Pharmacokinetics of recombinant interleukin 2 in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Cardiopulmonary toxicity of adoptive immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Myocardial injury after interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Interleukin-2 therapy for advanced renal cell carcinoma: radiographic evaluation of response and complications

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Reactivation of rheumatoid arthritis during continuous infusion of interleukin 2: evidence of lymphocytic control of rheumatoid disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Blood coagulation abnormalities during adoptive immunotherapy with interleukin-2 (r-Met Hu IL-2 [ala 125]).

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Nephrotoxicity of continuous intravenous infusion of recombinant interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

[Hypothyroidism after treatment with interleukin-2]

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Interleukin-2 toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Hyperbilirubinaemia in patients treated with recombinant human interleukin-2 (rIL-2)

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Adrenal insufficiency and interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Exacerbation of epidemic Kaposi's sarcoma with a combination of interleukin-2 and beta-interferon: results of a phase 2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Hypothyroidism and goitre during interleukin-2 therapy without LAK cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Unusual gastrointestinal complications of interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Adoptive immunotherapy with IL-2 results in the loss of delayed-type hypersensitivity responses and the development of immediate hypersensitivity to recall antigens

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Antierythrocyte autoantibody formation after therapy with interleukin-2 and gamma-interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Enhancement of a delayed hypersensitivity reaction to a contact allergen, by the systemic administration of interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Antibiotic prophylaxis to prevent catheter-related infections in recombinant interleukin-2-treated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Interleukin-2 immunotherapy in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Colonic perforation. An unusual complication of therapy with high-dose interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Atypical contrast reactions associated with systemic interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

The immunotherapy of human cancer with interleukin 2: present status and future directions

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Interleukin-2 induces early multisystem organ edema mediated by neutrophils

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Multiple organ failure during interleukin-2 administration and LAK cells infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Complete heart block due to interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

[Bullous dermatosis with linear IgA deposits along the basement membrane during treatment with gamma interferon and interleukin-2]

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Acute fatal leukoencephalopathy after interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Fibrinolysis, thrombocytopenia, and coagulation abnormalities complicating high-dose interleukin-2 immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Scintigraphic findings in patients with shoulder pain caused by interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Hypothyroidism after interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Nosocomial sepsis associated with interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Hypocholesterolemia in patients treated with recombinant interleukin-2: appearance of remnant-like lipoproteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Eosinophilic myocarditis associated with high-dose interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Interleukin-2 initiates metabolic responses associated with critical illness in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Ascites induced by interleukin-2 in the treatment of renal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Hypothyroidism and goiter during interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Transient focal neurologic deficits complicating interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

The neuroendocrine effects of interleukin-2 treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Case report: development of Hodgkin's disease in patient receiving long-term administration of dacarbazine and interleukin-2 for metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Recombinant interleukin-2-induced proteinuria: fact or artifact?

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Dermatologic changes associated with interleukin 2 administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Nephrotic syndrome associated with recombinant interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Hypothyroidism and goiter in a patient during treatment with interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Interleukin-2 therapy, central venous catheters, and nosocomial sepsis

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Immunologic effects of interleukin-2 adoptive immunotherapy in humans: acute in vitro anergy, in vivo antibody response to tetanus

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Life-threatening bullous skin eruptions during interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Thrombocytopenia during immunotherapy with interleukin-2 by constant infusion

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Acute interstitial nephritis during continuous intravenous administration of low-dose interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Erythema nodosum in a patient with renal cell carcinoma treated with interleukin 2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

The effects of interleukin 2 and alpha-interferon administration on hepatic drug metabolism in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Effects of cytokines on the liver

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Renal effects of continuous infusion of recombinant interleukin-2 in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Cardiorespiratory effects of immunotherapy with interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Contrast medium "recalls" interleukin-2 toxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Transient proteinuria during interleukin-2 therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Myocardial toxic effects during recombinant interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Severe myocarditis following high-dose interleukin-2 administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Marked disparity in incidence of bacterial infections in patients with the acquired immunodeficiency syndrome receiving interleukin-2 or interferon-gamma

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

Interleukin 2 and psoriasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/1418698

12 December 2020

10.2165/00002018-199207060-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1050062885

0 references

1 reference